logo-loader

Phase II Peprostat study 'a major milestone' says Ergomed's Andrew Mackie

Last updated: 02:18 21 Mar 2017 AEDT, First published: 22:18 20 Mar 2017 AEDT

Ergomed's (LON:ERGO) chief business officer Andrew Mackie and Ben Nichols, CEO of subsidiary Haemostatix spoke to Proactive's Andrew Scott about the start of recruiting for a phase IIb proof-of-concept study on Peprostat - which will be used to treat a surgical complication called intraoperative bleeding.

Ergomed Plc adds to co-development pipeline with Allergy Therapeutics deal

Andrew Mackie, chief business officer at Ergomed Plc (LON:ERGO), caught up with Proactive to discuss their co-development agreement with Allergy Therapeutics plc (LON:AGY). Under the terms of the collaboration, Ergomed will take the treatments for dust mite, tree pollen and grass pollen...

on 14/12/17